FOLD Stock Amicus Therapeutics Inc - Complete Overview

Nasdaq / Pharmaceutical Products / Healthcare / FOLD Stock

Amicus Therapeutics Inc (FOLD) price per share as of 24 May 2018
USD
Your sentiment
COLDTRENDOMETERHOT
Shares Outstanding 188.47M
Avg Daily Volume 2.55M
Market Cap 2.62B
Volatility 56.91% MEDIUM

AMICUS THERAPEUTICS INC (FOLD) OVERVIEW

FOLD stock is a pharmaceutical products company traded on Nasdaq. It is valued at 2.62B US dollars. There are 188.47M shares outstanding which Amicus Therapeutics Inc issued to investors. Volatility of the stock is MEDIUM, and the daily volume is 56.91% stock on average. It brought investors a total return of 100.88% over the last 12 months. Amicus Therapeutics Inc stock is relatively cheap. It's P/E ratio is below the market average.

Amicus Therapeutics Inc (FOLD) STOCK PRICE PERFORMANCE

FOLD SHAREHOLDER'S RETURN

Earnings Per Share 0.00
Dividends Per Share 0.00
12 Months Price Performance High
Total Return High

FOLD LATEST NEWS

Is Amicus On The Verge Of A Breakout?

Migalastat, treatment of Fabry disease, is in a period of significant revenue and regulatory growth.Technically speaking, Amicus appears poised for its next run-up.Fundamentals and a focused, driven m

Amicus Therapeutics' (FOLD) CEO John Crowley on Q1 2018 Results - Earnings Call Transcript

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q1 2018 Earnings Conference Call May 08, 2018 08:30 AM ET Executives Sara Pellegrino - Vice President of Investor Relations and Corporate Communications John Cr

Hedge Fund and Insider Trading News: John Paulson, Warren Buffett, Amicus Therapeutics, Inc. (FOLD), Workday Inc (WDAY), and More

John Paulson’s gold and special situations hedge funds are among those returning client capital as the firm narrows its focus after shedding almost $...

Amicus Therapeutics' (FOLD) CEO John Crowley on Q4 2017 Results - Earnings Call Transcript

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2017 Results Earnings Conference Call February 28, 2018, 08:30 AM ET Executives Sara Pellegrino - Senior Director, IR John Crowley - Chairman and Chief Execu

3 Things In Biotech You Should Learn Today: February 14, 2018

Exelixis shows promise outside of liver and kidney cancer.Amicus Therapeutics gets priority review to put Fabry disease on FOLD.Audentes makes a BOLD move in Crigler-Najjar syndrome.

Amicus Therapeutics: Positive Data For Pompe Disease And Recent Regulatory Developments

The innovation of medicines to service the rare disease market can deliver hopes to countless patients worldwide.Amicus recently filed the NDA for migalastat with the U.S. FDA as a potential treatment

Amicus Therapeutics Inc (FOLD) TECHNICAL INDICATORS

Name Value Action
RSI(14) 59.07 Buy
CMO(14) 18.14 Buy
ADX(14) 16.91 Neutral
Williams %R -24.87 Overbought

FOLD FORUM DISCUSSIONS